Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1

Anti-Cancer Drugs

Volumn 17, Issue 4, 2006, Pages 393-399

  Tsuruoka, Yuko ^a   Kamano, Toshiki ^a   Kitajima, Masayuki ^a   Kawai, Ken ^a   Watabe, Suguru ^a   Ochiai, Takumi ^b   Sakamoto, Kazuhiro ^a   Shirasaka, Tetsuhiko ^c  

^a JUNTENDO UNIVERSITY   (Japan)

^b Tokyo Metropolitan Health and Medical Treatment Corporation   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Gastrectomy; Gimeracil; Pharmacokinetics; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROURACIL; GIMERACIL; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; EATING; FEMALE; GASTRECTOMY; HUMAN; MALE; PARTIAL GASTRECTOMY; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SINGLE DRUG DOSE; STOMACH CANCER;

ADMINISTRATION, ORAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PYRIDINES; STOMACH NEOPLASMS; TEGAFUR; TIME FACTORS;

EID: 33748172885     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000203382.07114.0f     Document Type: Article

References (17)

1. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7:548-557.
2. Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, et al. Phase I study of S-1. Jpn J Cancer Chemother 1997; 24:2253-2264.
3. Shirasaka T, Shimamoto Y, Kato T, Fukushima M. Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil. Jpn J Cancer Chemother 1998; 25:371-384.
4. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivatives for advanced and recurrent gastrointestinal cancers. Oncology 1999; 57:202-210.
5. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34:1715-1720.
6. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000; 58:191-197.
7. Masuda H, Ikeda K, Toko K, Nagayama S, Kawaguchi Y, Hori K, et al. Disposition of components of new anti-cancer drug S-1 (1): absorption and excretion of components of S-1 after single administration to rats. Xenobio Metab Dispos 1997; 12:289-300.
8. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999; 5:2000-2005.
9. Kochi M, Fujii M, Takahashi M, Kaiga T, Morishita Y, Kobayashi M, et al. Examination of the effect of gastrectomy on pharmacokinetics of TS-1. Proc Jpn Soc Clin Oncol 2002; 37:520.
10. Kamano T, Tamura J, Azuma N, Katami A, Sato T, Uchida T, et al. Fundamental study on oral administration of pyrimidine fluoride preparations - especially on influence of gastrectomy on their absorption. Oncologia 1988; 21:74-79.
11. Sato T, Kamano T, Tamura J, Iwase H, Mikami Y, Sakakibara N. Effect of total gastrectomy on absorption of oral fluoropyrimidines. Oncologia 1990; 23:106-110.
12. Hanaue H, Okumura A, Sugano K, Kubo H, Tajima T, Mitomi T. Movement of 5-fluorouracil into blood circulation after oral administration according to the surgical procedure in post-operative adjuvant chemotherapy of gastric cancer. J Jpn Soc Cancer Ther 1993; 28:30-35.
13. Maehara Y, Takeuchi H, Oshiro T, Takahashi I, Inutsuka S, Baba H, et al. Effect of gastrectomy on the pharmacokinetics of tegafur, uracil, and 5-fluorouracil after oral administration of a 1:4 tegafur and uracil combination. Cancer Chemother Pharmacol 1994; 33:445-449.
14. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma, 13th ed. Tokyo: Kanehara; 1999.
15. Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, et al. Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 2003; 89:816-820.
16. Arai K, Iwasaki Y, Kimura Y, Takahashi K, Yamaguchi T, Honma, et al. Efficacy and safety of novel oral fluoropyrimidine anticancer drug TS-1 for advanced and recurrent gastric cancer patients. Jpn J Cancer Chemother 2003; 30:1297-1301.
17. Kinoshita T, Nashimoto A, Yamamura Y, Okamura T, Sasako M, Sakamoto J, et al. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Gastric Cancer 2004; 7:104-109.